GNCA - ジェノシア・バイオサイエンシズ (Genocea Biosciences Inc.) ジェノシア・バイオサイエンシズ

 GNCAのチャート


 GNCAの企業情報

symbol GNCA
会社名 Genocea Biosciences Inc (ジェノシア・バイオサイエンシズ)
分野(sector) Health Care   ヘルスケア
産業(industry) Biotechnology: Biological Products (No Diagnostic Substances)  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 ジェノセア・バイオサイエンス(Genocea Biosciences Inc.)はT細胞免疫力を利用してワクチンと免疫療法を開発する。同社はその発見プラットフォームであるAnTigen Lead Acquisition System(ATLAS)を使用して、一部はT細胞(または細胞)免疫反応によって作用するワクチンおよび免疫療法を設計する。同社は、第III相臨床開発における1つの製品候補であり、性器ヘルペスの治療のための免疫療法であるGEN-003を有する。また、パーソナライズされた癌ワクチン(GEN-009)に焦点を合わせた前臨床免疫腫瘍学プログラムを有する。そのGEN-009プログラムは、ATLASを利用して、個体の腫瘍に関連する患者新生抗原、または各患者に固有の新たに形成された抗原を同定する。   ジェノシア・バイオサイエンシズは、米国のバイオ医薬品企業。ATLASプラットフォ―ム技術を用いて新型ワクチンの開発に従事。単純ヘルペスウイルス2型(HSV-2)の治療薬や、肺炎球菌の感染予防用ワクチンの製品候補の開発を手掛ける。またクラミジア予防プログラム、HSV-2予防プログラム、マラリア予防プログラムなど開発プログラムを手掛ける。   Genocea's mission is to conquer cancer by developing personalized cancer immunotherapies in multiple tumor types. Our unique ATLAS™ platform comprehensively profiles each patient's T cell responses to potential targets, or antigens, on the tumor. ATLAS enables us to optimize the neoantigens for inclusion in our immunotherapies and exclude inhibitory antigens, Inhibigens™, that can exert an immunosuppressive effect. We are advancing two ATLAS-enabled programs: GEN-009, our neoantigen vaccine and GEN-011, our neoantigen-specific cell therapy using T cells derived from peripheral blood.
本社所在地 100 Acorn Park Drive Cambridge MA 02140 USA
代表者氏名 Katrine S. Bosley Katrine S. Bosley
代表者役職名 Chairman of the Board 取締役会会長
電話番号 +1 617-876-8191
設立年月日 38930
市場名 NASDAQ National Market System
ipoyear 2014年
従業員数 52人
url www.genocea.com
nasdaq_url https://www.nasdaq.com/symbol/gnca
adr_tso
EBITDA EBITDA(百万ドル) -43.25400
終値(lastsale) 0.8
時価総額(marketcap) 69300780
時価総額 時価総額(百万ドル) 62.71721
売上高 売上高(百万ドル) 0.00000
企業価値(EV) 企業価値(EV)(百万ドル) 33.67221
当期純利益 当期純利益(百万ドル) -47.92800
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Genocea Biosciences Inc revenues was not reported. Net loss decreased 30% to $20.3M. Lower net loss reflects Research and Development - Bal Val decrease of 40% to $12.3M (expense) General and administrative decrease of 35% to $936K (expense) stock based-Research and development decrease of 59% to $300K (expense).

 GNCAのテクニカル分析


 GNCAのニュース

   Genocea Biosciences up 7%; stock options granted to director  2021/09/29 19:45:47 Seeking Alpha
   Jennifer Herron, of ADC Therapeutics, Joins Genocea Biosciences'' Board of Directors  2021/09/13 20:52:00 Intrado Digital Media
CAMBRIDGE, Mass., Sept. 13, 2021 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (Nasdaq: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced that Jennifer Herron, Senior Vice President & Chief Commercial Officer at ADC Therapeutics SA ("ADCT"), has joined its board of directors.
   Genocea to Present at Upcoming Scientific and Investor Conferences  2021/09/07 23:40:00 Intrado Digital Media
CAMBRIDGE, Mass., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (Nasdaq: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, announced that senior leadership plans to present at the following virtual conferences in September.
   Herpes Simplex Virus (HSV) Vaccines Market Major Players Sanofi S.A., GlaxoSmithKline Plc., Genocea Biosciences, Inc., Vical, Inc.  2021/08/04 09:56:12 OpenPR
"Coherent Market Insights announced that its published an exclusive report namely Global Herpes Simplex Virus (HSV) Vaccines Market by Manufacturers, Regions, Type, and Application, Forecast to 2027 in its research database with report summary, table of content, research methodologies, and
   Genocea Biosciences, Inc. (GNCA) CEO Chip Clark on Q2 2021 Results - Earnings Call Transcript  2021/07/29 21:18:06 Seeking Alpha
   Herpes Simplex Virus (HSV) Vaccines Market Major Players Sanofi S.A., GlaxoSmithKline Plc., Genocea Biosciences, Inc., Vical, Inc.  2021/08/04 09:56:12 OpenPR
"Coherent Market Insights announced that its published an exclusive report namely Global Herpes Simplex Virus (HSV) Vaccines Market by Manufacturers, Regions, Type, and Application, Forecast to 2027 in its research database with report summary, table of content, research methodologies, and
   Genocea Biosciences, Inc. (GNCA) CEO Chip Clark on Q2 2021 Results - Earnings Call Transcript  2021/07/29 21:18:06 Seeking Alpha
   Genocea Biosciences, Inc. 2021 Q2 - Results - Earnings Call Presentation  2021/07/29 16:55:46 Seeking Alpha
   Genocea Biosciences EPS misses by $0.02  2021/07/29 11:21:44 Seeking Alpha
   Genocea to Host Second Quarter 2021 Corporate Update Conference Call & Webcast  2021/07/22 21:05:00 Intrado Digital Media
CAMBRIDGE, Mass., July 22, 2021 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation cancer immunotherapies, will host its second quarter 2021 financial results and corporate update conference call and live audio webcast on Thursday, July 29 t h at 8:30 a.m. E.T.
   Herpes Simplex Virus (HSV) Vaccines Market Growth In The Market With Major Vendors Sanofi S.A., GlaxoSmithKline Plc., Genocea Biosciences, Inc., Vical, Inc.  2020/12/17 05:13:13 OpenPR
Herpes simplex virus (HSV) is known for causing herpes infection. This is majorly found on genitals or mouth and can also be seen on various body parts. There are two types of herpes simplex virus, type 1 (HSV-1) and type
   Mono Vaccines (Epstein - Barr virus) Market Major Players analysis Cancer Research UK, National Institutes of Health, Chinese University of Hong Kong, Genocea Biosciences, Inc., Dana-Farber Cancer Institute, German Cancer Research Institute, and Universit  2020/12/10 11:41:18 OpenPR
"The Mono Vaccines (Epstein - Barr virus) Market 2020 - 2027 report covers the important factors driving the growth of the market, untapped opportunities for manufacturers, trends and developments shaping the dynamics of the market and other insights across various
   The Week Ahead In Biotech: Supernus, Sanofi Await FDA Decisions  2020/11/08 17:47:42 Benzinga
Biotech stocks turned around with the broader market in the week ended Nov. 6, as investors warmed to the idea of a split Congress and a change of guard at the White House. The week witnessed a flurry of earnings from several smid-cap companies. Bluebird bio Inc. (NASDAQ: BLUE ) shares came under pressure after it announced a push back in the timeline for the regulatory filing for its gene therapy to treat sickle cell disease. Biogen Inc. (NASDAQ: BIIB ) was also in the news over an FDA roadblock regarding its Alzheimer's drug aducanumab. On the M&A front, Merck & Co. Inc. (NYSE: MRK ) announced a $2.75 billion deal to buy oncology-focused biopharma VelosBio Inc. Here are the key biotech events to watch out for in the unfolding week: Conferences American College of Rheumatology, or ACR, Convergence 2020: Nov. 5-9 Credit Suisse 29th Annual Virtual Healthcare Conference: Nov. 9-10 35th Annual Meeting of The Society for Immunotherapy of Cancer, or SITC: Nov. 9-14 American Academy of Ophthalmology, or AAO, 2020 Virtual meeting: Nov.
   Personalized Cancer Vaccines Market (COVID - 19 Updates) Complete Survey 2020 Insights, Demand, Analysis, Type, Size and Share, Leading Players are Gritstone Oncology, Personalis Inc, Genocea Biosciences, Inc., F. Hoffmann-La Roche Ltd, CureVac AG  2020/10/08 17:56:36 OpenPR
This Personalized Cancer Vaccines Market research report is a detailed synopsis on the study of industry and its impact on the market environment. By systematically understanding and keeping into thought customer requirement, one step or combination of many steps has
   Global Precision Medicine Market to Show Tremendous Growth by 2027 | Leading Players-Neon Therapeutics, Moderna, Inc, Merck & Co., Inc, Bayer AG, PERSONALIS INC, GENOCEA BIOSCIENCES, INC., F. Hoffmann-La Roche Ltd  2020/10/08 15:36:19 OpenPR
DBMR has added a new report titled Global Precision Medicine Market with analysis provides the insights which bring marketplace clearly into the focus and thus help organizations make better decisions. The data and the information regarding the industry are taken from

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 ジェノシア・バイオサイエンシズ GNCA Genocea Biosciences Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)